Biotech: Page 2


  • An AbbVie sign is seen on the outside of a building in California.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    AbbVie to buy immune drug developer Landos

    Worth about $138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohn’s.

    By March 25, 2024
  • A Novo Nordisk sign is seen on the side of a building.
    Image attribution tooltip
    hapabapa via Getty Images
    Image attribution tooltip

    Novo to acquire heart failure drug in $1B deal for Cardior

    Cardior’s therapy is currently in mid-stage testing and, should the deal close, Novo plans to start another Phase 2 trial.

    By March 25, 2024
  • Colorized scanning electron micrograph of a natural killer cell from a human donor. Explore the Trendline
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Cell therapy

    Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches.

    By BioPharma Blog staff
  • Scientists wearing full protective suit working in the laboratory
    Image attribution tooltip
    sanjeri via Getty Images
    Image attribution tooltip
    Sponsored by Quest Diagnostics

    The future of companion diagnostic (CDx) development: Why commercialization is key

    As precision medicine expands into a growing number of therapeutic areas, the “one size fits all” approach to drug development is becoming less common.

    March 25, 2024
  • A photo of a sign showing the Food and Drug Administration logo
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA clears first-of-its-kind Duchenne drug for broad use

    The approval of Italfarmaco’s Duvyzat is the first for an oral, non-steroidal Duchenne drug and was issued for all patients at least six years of age, regardless of their genetic underpinnings.

    By March 22, 2024
  • A stock photo of wooden blocks illustrating layoffs
    Image attribution tooltip
    cagkansayin via Getty Images
    Image attribution tooltip

    NextCure to lay off 37% of staff, dial back research plans

    The job cuts at the cancer biotech will primarily impact manufacturing roles, but will touch on several other parts of the organization too, the company said.

    By March 21, 2024
  • Mark McKenna, the CEO of Mirador Therapeutics, poses for a photo.
    Image attribution tooltip
    Permission granted by Mirador Therapeutics
    Image attribution tooltip
    Emerging biotech

    Mirador debuts with $400M, picking up where immune drugmaker Prometheus left off

    The financing for the startup, which is led by former executives of a biotech Merck recently bought for nearly $11 billion, is the sector’s largest for a privately held company this year.

    By March 21, 2024
  • An illustration of engineered CAR-T cells attacking a cancer cell.
    Image attribution tooltip
    Nemes Laszlo via Getty Images
    Image attribution tooltip
    Emerging biotech

    Capstan heats up ‘in vivo’ cell therapy chase with $175M fundraise

    The high-profile startup, co-founded by CAR-T innovator Carl June, will use the funds to bring an autoimmune disease treatment into proof-of-concept studies.

    By March 20, 2024
  • An illustration of T cells attacking a cancer cell
    Image attribution tooltip
    Peddalanka Ramesh Babu via Getty Images
    Image attribution tooltip
    Emerging biotech

    Clasp launches with $150M and a plan for precision cancer immunotherapies

    The company claims its approach could yield more effective and safer T-cell engagers, a type of cancer medicine that’s attracted significant interest from drugmakers in recent years.

    By March 20, 2024
  • A conceptual illustration of neural activity in a brain.
    Image attribution tooltip
    nopparit via Getty Images
    Image attribution tooltip

    Engrail’s precision psychiatry drugs get more buy in from venture investors

    The San Diego-based startup added $157 million in new funding to back a drug for generalized anxiety order that’s now in human testing.

    By March 19, 2024
  • A photo of Bluebird bio signage in a corporate lobby
    Image attribution tooltip
    Permission granted by Bluebird bio
    Image attribution tooltip

    Bluebird, short on cash, takes on $175M in debt financing

    The funding could extend the cash-strapped gene therapy maker’s financial runway to 2026, but only if the company successfully hits certain milestones.

    By March 18, 2024
  • Doctor hands texting on a smart phone
    Image attribution tooltip

    shutterstock.com/VAlekStudio

    Image attribution tooltip
    Sponsored by Veeva

    Give HCPs a proactive way to reach your field team: Add inbound

    HCPs today want inbound channels for help when they need it. See how you can meet their preferences.

    By Paul Shawah, Executive Vice President of Strategy, Veeva • March 18, 2024
  • Woman writing on a glass board
    Image attribution tooltip
    PeopleImages via Getty Images
    Image attribution tooltip
    Sponsored by Cardinal Health Sonexus™ Access and Patient Support

    The digital divide: Balancing automation and human interaction regardless of the patient support program model

    Balancing automated patient support with human touch is key in healthcare. Hybrid models offer a pragmatic path forward, prioritizing patient-centricity.

    March 18, 2024
  • A street sign for Wall Street in front of the facade of the New York Stock Exchange.
    Image attribution tooltip
    JaysonPhotography via Getty Images
    Image attribution tooltip

    Contineum, a startup born from a Roche buyout, files for IPO

    The biotech, formed as a successor to a company Roche acquired in 2018, has two drugs in clinical testing for neurological and immune diseases.

    By March 17, 2024
  • A photo of a Madrigal Pharmaceuticals' MASH drug Rezdiffra.
    Image attribution tooltip
    Courtesy of Madrigal Pharmaceuticals
    Image attribution tooltip

    Madrigal, FDA approval in hand, outlines plan to sell MASH drug

    The company expects initial uptake of Rezdiffra, which costs $47,400 per year, to be slow as doctors and insurers establish the protocols needed to find patients eligible for treatment.

    By March 15, 2024
  • A 3D visualization of antibody drug conjugates.
    Image attribution tooltip
    Love Employee via Getty Images
    Image attribution tooltip

    German biotech Tubulis cashes in on ADC ‘momentum’ with €128M financing

    The funding for the startup, which partnered with Bristol Myers Squibb last year, adds to a surge of recent investments in developers of antibody-drug conjugates.

    By March 14, 2024
  • A Novartis logo is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip
    Emerging biotech

    IFM, an unorthodox biotech startup, scores third buyout with Novartis deal

    With a decision by the Swiss pharma to acquire another one of its subsidiaries, IFM Therapeutics has now sold three spin-offs for a total of $700 million upfront and the potential for billions more in future payments.

    By Kristin Jensen • March 13, 2024
  • An illustration of engineered CAR-T cells attacking a cancer cell.
    Image attribution tooltip
    Nemes Laszlo via Getty Images
    Image attribution tooltip

    Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease

    The partnership is designed to help the company stand out in what’s quickly become one of the industry’s hottest areas of drug research.

    By March 12, 2024
  • A photograph of a box of Amylyx Pharmaceuticals' ALS medicine Relyvrio
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip
    ALS drug development

    After surprise trial failure, ALS doctors brace for one less treatment option

    Physicians have been preparing for tough conversations with patients on Amylyx's drug since negative confirmatory trial results in March.

    By Updated April 4, 2024
  • Brain scans are seen in a stock image
    Image attribution tooltip
    sudok1 via Getty Images
    Image attribution tooltip

    Boehringer, Sosei Heptares team up in schizophrenia drug deal

    Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple neurological diseases.

    By March 11, 2024
  • A photograph of Amylyx Pharmaceuticals cofounders Josh Cohen and Justin Klee.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip
    Q&A

    Amylyx CEOs look for a path forward following major setback

    Justin Klee and Joshua Cohen spoke to BioPharma Blog about the next steps for their company, which is considering pulling its only product from market after the drug failed a confirmatory study in ALS.

    By March 11, 2024
  • The Wall Street sign in the Financial District of Lower Manhattan in New York City.
    Image attribution tooltip
    hapabapa via Getty Images
    Image attribution tooltip

    Biotech stock fundings headed for best quarter in 3 years, Jefferies says

    Publicly traded companies raised nearly $10 billion in follow-on stock offerings in January and February, a financing surge that’s driving a “sector recovery,” the investment bank said.

    By March 11, 2024
  • Young woman in a hospital being registered using a tablet computer
    Image attribution tooltip
    andresr via Getty Images
    Image attribution tooltip
    Sponsored by PurpleLab

    Can using SDoH data help identify patient populations who could benefit from weight loss drugs?

    SDoH data can help companies understand the footprint of weight loss medications in the market and their impact across populations.

    March 11, 2024
  • The logo of Amylyx Pharmaceuticals is seen through an office window.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx ALS drug fails crucial study, putting company’s future in doubt

    The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

    By Updated March 8, 2024
  • The Nasdaq Marketplace is seen on March 01, 2024 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Boundless Bio, a Bayer-backed cancer biotech, seeks an IPO

    The startup, which has raised nearly $254 million privately, is in early testing with drugs designed to target particularly tough-to-treat tumors.

    By March 7, 2024
  • A stock market graph overlaid on a laptop and stack of coins.
    Image attribution tooltip
    Stadtratte via Getty Images
    Image attribution tooltip

    European VC Invivo readies its latest fund to back new biotechs

    The Barcelona-based firm, which is targeting about 100 million euros for the new fund, is eyeing investments in AI, synthetic biology, and cell and gene therapy.

    By March 6, 2024